Outcomes over 5 years after diagnosis of SLE in groups A, B, and C. Values are mean ± SD or n (%).
| Outcomes | Group A, AM Intake > 60% of Time, n = 236 | Group B, AM Intake < 60% of Time, n = 88 | Group C, Non-AM intake, n = 135 | p |
|---|---|---|---|---|
| Increase in SDI | 0.61 ± 0.95 | 0.85 ± 1.30 | 1.01 ± 1.33 | 0.003 |
| Flares | 2.66 ± 1.96 | 3.16 ± 2.23 | 3.23 ± 2.79 | 0.04 |
| LDA at yr 5 | 194 (82.2) | 67 (76.1) | 95 (70.4) | 0.03 |
| Adjusted mean SLEDAI-2K | 4.36 ± 2.90 | 4.42 ± 2.46 | 4.83 ± 3.74 | 0.35 |
| Cumulative doses of GCS, g | 14.60 ± 11.06 | 20.22 ± 13.35 | 23.50 ± 15.04 | < 0.001 |
| AM-related retinal toxicity | 1 (0.4) | 1 (1.1) | 0 (0) | 0.45 |
AM: antimalarial agent; GCS: glucocorticosteroids; LDA: low disease activity; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLE: systemic lupus erythematosus; SLEDAI-2K: SLE Disease Activity Index 2000.